1. Assessment of symptom burden and adherence to respiratory medications in individuals self-reporting a diagnosis of COPD within a community pharmacy setting 
Suzanne G. Bollmeier, Terry L. Seaton, Theresa R. Prosser, Yi-Ting Chou, Kristine Reckenberg, Beth Hahn, Richard H. Stanford, Riju Ray 
Journal of the American Pharmacists Association 
Volume 59, Issue 4, Pages e1 (July 2019)
DOI: /j.japh
Copyright © 2019 American Pharmacists Association® Terms and Conditions

2. Figure 1
Criteria for assessment of GOLD category classification (based on the GOLD 2016 report24). †GOLD grade is used as an alternative to exacerbation history to classify risk of exacerbation. GOLD grade (based on postbronchodilator FEV1) was separated from the ABCD group classification in the reports from 2017, with no changes to the symptom burden or exacerbation history criteria.1,28,29 Abbreviations used: CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council dyspnea scale. Figure adapted from the GOLD 2016 report.24 Copyright 2018, Global Initiative for Chronic Obstructive Lung Disease, reprinted with permission.
Journal of the American Pharmacists Association  , e1DOI: ( /j.japh )
Copyright © 2019 American Pharmacists Association® Terms and Conditions